Board MeetingMay 6, 2026, 08:32 AM
Veru Inc. to Host Q2 2026 Earnings Call & Business Update May 13
AI Summary
Veru Inc. announced it will host a conference call and audio webcast on Wednesday, May 13, 2026, to discuss its fiscal 2026 second quarter financial results and provide a business update. The company also provided updates on its late-stage drug development programs, enobosarm and sabizabulin. The Phase 2b PLATEAU clinical study for enobosarm is enrolling, with interim data expected in Q1 2027 and final data in Q4 2027, building on positive results from the completed Phase 2b QUALITY study.
Key Highlights
- Veru Inc. to host a conference call and audio webcast on May 13, 2026, at 8:00 a.m. ET.
- The call will discuss fiscal 2026 second quarter financial results and provide a business update.
- Enobosarm Phase 2b PLATEAU clinical study is currently enrolling approximately 200 older patients.
- Interim analysis data for the PLATEAU study is expected in Q1 2027, with final data in Q4 2027.
- The Phase 2b QUALITY clinical study was positive, showing enobosarm plus semaglutide led to greater fat loss.
- Sabizabulin is being developed for chronic inflammation related to atherosclerotic cardiovascular disease.
Price Impact
More from VERU